See the DrugPatentWatch profile for tazorac
Why would tazorac be withdrawn from the U.S. market?
Tazorac (tazarotene) is an acne/psoriasis topical retinoid. A product like this is usually withdrawn for one of a few practical reasons: it can be replaced by another product/strength, the manufacturer stops marketing it in the U.S., regulatory action is taken, or the product faces business/supply issues.
Was the withdrawal a safety issue?
For many topical dermatology products, “withdrawn” notices can be tied to safety, but the reason must be verified from the specific withdrawal notice (often from the manufacturer or regulators). Without the exact notice or date, the most accurate answer is that withdrawals can be safety-related only if regulators or the manufacturer explicitly say so; otherwise it is often supply/market-related.
Was tazorac replaced by a generic or another product?
A common pattern is that branded dermatology products get discontinued in favor of generics or different formulations. If a newer/cheaper equivalent became the primary marketed option, the brand may be withdrawn even though the active ingredient remains available.
What official sources would confirm the real reason?
The definitive explanation typically comes from one of these:
- FDA communications tied to the product (for regulatory actions)
- The manufacturer’s discontinuation/withdrawal notice
- FDA drug labeling or National Drug Code (NDC) status changes
What I need to give you the exact reason
“Tazorac” can appear under different NDCs and strengths (cream vs gel), and withdrawals can be partial (some strengths) or complete (all presentations). If you share either:
- the strength/form (cream or gel), or
- the NDC, or
- the approximate year/date you saw the withdrawal
…I can narrow down the specific withdrawal and state the stated reason from the relevant notice.
Sources
I can’t cite the withdrawal reason yet because no source links or dates were provided.